NCT05125068Phase 2Terminated

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

Study sponsor: Eledon Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-07-31Actual
Enrollment · participants24Actual
Source updated2024-03-26Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview